Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. rAd5 Generation
2.2. ELISpot
2.3. TC-1 Challenge Model
2.4. Therapeutic Immunization and Immunotherapy
2.5. Analysis of Tumor Infiltrating Cells (TILs) by Flow Cytometry
2.6. Flow Cytometry on Blood Cells from Small Tumor Model Animals
2.7. Statistics
3. Results
3.1. Immunogenicity of Wildtype and Modified E6E7 Therapeutic Vaccines for HPV16
3.2. Mucosal Application of Antigen-Specific rAd5 Reduces Tumor Size
3.3. Immunization with Ad-HPV-16 Generates a Cytotoxic Tumor Microenvironment
3.4. Vaccination with rAd5 Vectors Expressing Non-Oncogenic E6E7 Led to Tumor Reduction
3.5. Mucosal Application of Antigen-Specific rAd5 Generates Antigen-Specific TEM Cells in a Small Tumor Model
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- De Sanjose, S.; Serrano, B.; Tous, S.; Alejo, M.; Lloveras, B.; Quiros, B.; Clavero, O.; Vidal, A.; Ferrandiz-Pulido, C.; Pavon, M.A.; et al. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2018, 2, pky045. [Google Scholar] [CrossRef]
- Muhr, L.S.A.; Eklund, C.; Dillner, J. Towards quality and order in human papillomavirus research. Virology 2018, 519, 74–76. [Google Scholar] [CrossRef]
- Hildesheim, A.; Gonzalez, P.; Kreimer, A.R.; Wacholder, S.; Schussler, J.; Rodriguez, A.C.; Porras, C.; Schiffman, M.; Sidawy, M.; Schiller, J.T.; et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am. J. Obstet. Gynecol. 2016, 215, 212.e1–212.e15. [Google Scholar] [CrossRef] [PubMed]
- Ho, G.Y.; Bierman, R.; Beardsley, L.; Chang, C.J.; Burk, R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338, 423–428. [Google Scholar] [CrossRef] [PubMed]
- Ljubojevic, S.; Skerlev, M. HPV-associated diseases. Clin. Dermatol. 2014, 32, 227–234. [Google Scholar] [CrossRef]
- Khallouf, H.; Grabowska, A.K.; Riemer, A.B. Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines 2014, 2, 422–462. [Google Scholar] [CrossRef]
- Hoffman, S.R.; Le, T.; Lockhart, A.; Sanusi, A.; dal Santo, L.; Davis, M.; McKinney, D.A.; Brown, M.; Poole, C.; Willame, C.; et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review. Int. J. Cancer 2017, 141, 8–23. [Google Scholar] [CrossRef] [PubMed]
- Stern, P.L.; van der Burg, S.H.; Hampson, I.N.; Broker, T.R.; Fiander, A.; Lacey, C.J.; Kitchener, H.C.; Einstein, M.H. Therapy of human papillomavirus-related disease. Vaccine 2012, 30 (Suppl. S5), F71–F82. [Google Scholar] [CrossRef]
- Cheng, S.; Schmidt-Grimminger, D.C.; Murant, T.; Broker, T.R.; Chow, L.T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 1995, 9, 2335–2349. [Google Scholar] [CrossRef]
- Moody, C.A.; Laimins, L.A. Human papillomavirus oncoproteins: Pathways to transformation. Nat. Rev. Cancer 2010, 10, 550–560. [Google Scholar] [CrossRef]
- Chabeda, A.; Yanez, R.J.R.; Lamprecht, R.; Meyers, A.E.; Rybicki, E.P.; Hitzeroth, I.I. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018, 5, 46–58. [Google Scholar] [CrossRef] [PubMed]
- Borysiewicz, L.K.; Fiander, A.; Nimako, M.; Man, S.; Wilkinson, G.W.; Westmoreland, D.; Evans, A.S.; Adams, M.; Stacey, S.N.; Boursnell, M.E. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347, 1523–1527. [Google Scholar] [CrossRef] [PubMed]
- Ding, Z.; Ou, R.; Ni, B.; Tang, J.; Xu, Y. Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice. Clin. Vaccine Immunol. 2013, 20, 1027–1033. [Google Scholar] [CrossRef]
- Juarez, V.; Pasolli, H.A.; Hellwig, A.; Garbi, N.; Arregui, A.C. Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice. Open Virol. J. 2012, 6, 270–276. [Google Scholar] [CrossRef] [PubMed]
- Khan, S.; Oosterhuis, K.; Wunderlich, K.; Bunnik, E.M.; Bhaggoe, M.; Boedhoe, S.; Karia, S.; Steenbergen, R.D.M.; Bosch, L.; Serroyen, J. Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease. Int. J. Cancer 2017, 141, 393–404. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.J.; Yang, A.; Wu, T.C.; Hung, C.F. Immunotherapy for human papillomavirus-associated disease and cervical cancer: Review of clinical and translational research. J. Gynecol. Oncol. 2016, 27, e51. [Google Scholar] [CrossRef]
- McCarthy, C.; Youde, S.J.; Man, S. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. Int. J. Cancer 2006, 118, 2514–2521. [Google Scholar] [CrossRef]
- Perez, S.; Zimet, G.D.; Tatar, O.; Stupiansky, N.W.; Fisher, W.A.; Rosberger, Z. Human Papillomavirus Vaccines: Successes and Future Challenges. Drugs 2018, 78, 1385–1396. [Google Scholar] [CrossRef]
- Rice, A.E.; Latchman, Y.E.; Balint, J.P.; Lee, J.H.; Gabitzsch, E.S.; Jones, F.R. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther. 2015, 22, 454–462. [Google Scholar] [CrossRef]
- Trimble, C.L.; Trimble, C.L.; Morrow, M.P.; Kraynyak, K.A.; Shen, X.; Dallas, M.; Yan, J.; Edwards, L.; Parker, R.L.; Denny, L.; et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015, 386, 2078–2088. [Google Scholar] [CrossRef]
- Wieking, B.G.; Vermeer, D.W.; Spanos, W.C.; Lee, K.M.; Vermeer, P.; Lee, W.T.; Xu, Y.; Gabitzsch, E.S.; Balcaitis, S.; Balint, J.P., Jr.; et al. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 2012, 19, 667–674. [Google Scholar] [CrossRef] [PubMed]
- McIlwain, D.R.; Chen, H.; Rahil, Z.; Bidoki, N.H.; Jiang, S.; Bjornson, Z.; Kolhatkar, N.S.; Martinez, C.J.; Gaudilliere, B.; Hedou, J. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell Host Microbe 2021, 29, 1828–1837.e5. [Google Scholar] [CrossRef] [PubMed]
- Liebowitz, D.; Gottlieb, K.; Kolhatkar, N.S.; Garg, S.J.; Asher, J.M.; Nazareno, J.; Kim, K.; McIlwain, D.R.; Tucker, S.N. Efficacy, immunogenicity, and safety of an oral influenza vaccine: A placebo-controlled and active-controlled phase 2 human challenge study. Lancet Infect. Dis. 2020, 20, 435–444. [Google Scholar] [CrossRef]
- Kim, L.; Liebowitz, D.; Lin, K.; Kasparek, K.; Pasetti, M.F.; Garg, S.J.; Gottlieb, K.; Trager, G.; Tucker, S.N. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight 2018, 3, e121077. [Google Scholar] [CrossRef] [PubMed]
- Kim, L.; Martinez, C.J.; Hodgson, K.A.; Trager, G.R.; Brandl, J.R.; Sandefer, E.P.; Doll, W.J.; Liebowitz, D.; Tucker, S.N. Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule. Sci. Rep. 2016, 6, 37295. [Google Scholar] [CrossRef]
- Liebowitz, D.; Lindbloom, J.D.; Brandl, J.R.; Garg, S.J.; Tucker, S.N. High titre neutralising antibodies to influenza after oral tablet immunisation: A phase 1, randomised, placebo-controlled trial. Lancet Infect. Dis. 2015, 15, 1041–1048. [Google Scholar] [CrossRef]
- Johnson, S.; Martinez, C.I.; Tedjakusuma, S.N.; Peinovich, N.; Dora, E.G.; Birch, S.M.; Kajon, A.E.; Werts, A.D.; Tucker, S.N. Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model. J. Infect. Dis. 2022, 225, 34–41. [Google Scholar] [CrossRef]
- Flitter, B.A.; Braun, M.R.; Tucker, S.N. Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens. Vaccines 2022, 10, 593. [Google Scholar] [CrossRef]
- Cummings, J.F.; Tucker, S. Potent Immune Responses to Norovirus G1.1 Evaluated in Elderly Subjects following Oral Tablet Delivery in a Phase 1 Placebo-Controlled Study. In Proceedings of the World Vaccine Congress 2022, Barcelona, Spain, 11–14 October 2022. [Google Scholar]
- Johnson, S.; Martinez, C.I.; Jegede, C.B.; Gutierrez, S.; Cortese, M.C.; Martinez, J.; Garg, S.J.; Peinovich, N.; Dora, E.G.; Tucker, S.N. SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trial. medRxiv 2022. [Google Scholar] [CrossRef]
- Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355. [Google Scholar] [CrossRef]
- Li, C.; Cang, W.; Gu, Y.; Chen, L.; Xiang, Y. The anti-PD-1 era of cervical cancer: Achievement, opportunity, and challenge. Front. Immunol. 2023, 14, 1195476. [Google Scholar] [CrossRef] [PubMed]
- Callahan, M.K.; Postow, M.A.; Wolchok, J.D. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front. Oncol. 2014, 4, 385. [Google Scholar] [CrossRef] [PubMed]
- Chen, Z.; Pang, N.; Du, R.; Zhu, Y.; Fan, L.; Cai, D.; Ding, Y.; Ding, J. Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells. Mediat. Inflamm. 2016, 2016, 6891482. [Google Scholar] [CrossRef] [PubMed]
- Fu, J.; Malm, I.J.; Kadayakkara, D.K.; Levitsky, H.; Pardoll, D.; Kim, Y.J. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res. 2014, 74, 4042–4052. [Google Scholar] [CrossRef]
- Peng, S.; Tan, M.; Li, Y.D.; Cheng, M.A.; Farmer, E.; Ferrall, L.; Gaillard, S.; Roden, R.B.S.; Hung, C.F.; Wu, T.C. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. Cancer Immunol. Immunother. 2021, 70, 1049–1062. [Google Scholar] [CrossRef]
- Mkrtichyan, M.; Chong, N.; Abu Eid, R.; Wallecha, A.; Singh, R.; Rothman, J.; Khleif, S.N. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J. Immunother. Cancer 2013, 1, 15. [Google Scholar] [CrossRef]
- Roberts, J.N.; Buck, C.B.; Thompson, C.D.; Kines, R.; Bernardo, M.; Choyke, P.L.; Lowy, D.R.; Schiller, J.T. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 2007, 13, 857–861. [Google Scholar] [CrossRef]
- Berraondo, P.; Nouze, C.; Preville, X.; Ladant, D.; Leclerc, C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res. 2007, 67, 8847–8855. [Google Scholar] [CrossRef]
- Lin, K.Y.; Guarnieri, F.G.; Staveley-O’Carroll, K.F.; Levitsky, H.I.; August, J.T.; Pardoll, D.M.; Wu, T.C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996, 56, 21–26. [Google Scholar]
- McConnell, E.L.; Basit, A.W.; Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J. Pharm. Pharmacol. 2008, 60, 63–70. [Google Scholar] [CrossRef]
- Braun, M.R.; Martinez, C.I.; Dora, E.G.; Showalter, L.J.; Mercedes, A.R.; Tucker, S.N. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2. Front. Immunol. 2023, 14, 1086035. [Google Scholar] [CrossRef]
- Jordanova, E.S.; Gorter, A.; Ayachi, O.; Prins, F.; Durrant, L.G.; Kenter, G.G.; van der Burg, S.H.; Fleuren, G.J. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients? Clin. Cancer Res. 2008, 14, 2028–2035. [Google Scholar] [CrossRef] [PubMed]
- Nielsen, M.; Lundegaard, C.; Worning, P.; Lauemoller, S.L.; Lamberth, K.; Buus, S.; Brunak, S.; Lund, O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003, 12, 1007–1017. [Google Scholar] [CrossRef]
- Lundegaard, C.; Lamberth, K.; Harndahl, M.; Buus, S.; Lund, O.; Nielsen, M. NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008, 36, W509–W512. [Google Scholar] [CrossRef]
- Scallan, C.D.; Tingley, D.W.; Lindbloom, J.D.; Toomey, J.S.; Tucker, S.N. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin. Vaccine Immunol. 2013, 20, 85–94. [Google Scholar] [CrossRef] [PubMed]
- Simpson-Herren, L.; Lloyd, H.H. Kinetic parameters and growth curves for experimental tumor systems. Cancer Chemother. Rep. 1970, 54, 143–174. [Google Scholar] [PubMed]
- Boursnell, M.E.; Rutherford, E.; Hickling, J.K.; Rollinson, E.A.; Munro, A.J.; Rolley, N.; McLean, C.S.; Borysiewicz, L.K.; Vousden, K.; Inglis, S.C. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996, 14, 1485–1494. [Google Scholar] [CrossRef] [PubMed]
- IEDB Analysis Resource. Available online: http://tools.iedb.org/main/tcell/ (accessed on 2 February 2019).
- Scott, E.N.; Gocher, A.M.; Workman, C.J.; Vignali, D.A.A. Regulatory T Cells: Barriers of Immune Infiltration into the Tumor Microenvironment. Front. Immunol. 2021, 12, 702726. [Google Scholar] [CrossRef]
- Raskov, H.; Orhan, A.; Christensen, J.P.; Gogenur, I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br. J. Cancer 2021, 124, 359–367. [Google Scholar] [CrossRef]
- Langel, S.N.; Johnson, S.; Martinez, C.I.; Tedjakusuma, S.N.; Peinovich, N.; Dora, E.G.; Kuehl, P.J.; Irshad, H.; Barrett, E.G.; Werts, A.D.; et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci. Transl. Med. 2022, 14, eabn6868. [Google Scholar] [CrossRef]
- Zottnick, S.; Voss, A.L.; Riemer, A.B. Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations. Front. Immunol. 2020, 11, 1750. [Google Scholar] [CrossRef] [PubMed]
- Trimble, C.L.; Clark, R.A.; Thoburn, C.; Hanson, N.C.; Tassello, J.; Frosina, D.; Kos, F.; Teague, J.; Jiang, Y.; Barat, N.C. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J. Immunol. 2010, 185, 7107–7114. [Google Scholar] [CrossRef] [PubMed]
- Tucker, S.N. Oral Tablet Vaccination to SARS-CoV-2 Induces Long Lasting Cross-reactive Mucosal Antibody Responses in Humans. In Proceedings of the World Vaccine Congress 2022, Barcelona, Spain, 11–14 October 2022. [Google Scholar]
- Ibrahim Khalil, A.; Zhang, L.; Muwonge, R.; Sauvaget, C.; Basu, P. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: A systematic review and meta-analysis of phase II/III clinical trials. BMJ Open 2023, 13, e069616. [Google Scholar] [CrossRef] [PubMed]
- Bruni, L.; Saura-Lazaro, A.; Montoliu, A.; Brotons, M.; Alemany, L.; Diallo, M.S.; Afsar, O.Z.; LaMontagne, D.S.; Mosina, L.; Contreras, M. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev. Med. 2021, 144, 106399. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Braun, M.R.; Moore, A.C.; Lindbloom, J.D.; Hodgson, K.A.; Dora, E.G.; Tucker, S.N. Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study. Vaccines 2024, 12, 955. https://doi.org/10.3390/vaccines12090955
Braun MR, Moore AC, Lindbloom JD, Hodgson KA, Dora EG, Tucker SN. Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study. Vaccines. 2024; 12(9):955. https://doi.org/10.3390/vaccines12090955
Chicago/Turabian StyleBraun, Molly R., Anne C. Moore, Jonathan D. Lindbloom, Katherine A. Hodgson, Emery G. Dora, and Sean N. Tucker. 2024. "Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study" Vaccines 12, no. 9: 955. https://doi.org/10.3390/vaccines12090955